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In Vitro and In Vivo Genotoxicity of
1,3-Butadiene and Metabolites
by Gail Theall Arce,* Daniel R. Vincent,* Mary Jane
Cunningham,t Wai Nang Choy,* and Awni M. Sarrif*
1,3-Butadiene and two major genotoxic metabolites 3,4-epoxybutene (EB) and 1,2:3,4-diepoxybutane
(DEB) were used as model compounds to determine ifgenetic toxicity findings in animal and human cells
can aid in extrapolating animal toxicity data to man. Sister chromatid exchange (SCE) and micronucleus
induction results indicated 1,3-butadiene was genotoxic in the bone marrow ofthe mouse but not the rat.
This paralleled the chronic bioassays which showed mice to be more susceptible than rats to 1,3-butadiene
carcinogenicity. However, 1,3-butadiene did not induce unscheduled DNA synthesis (UDS) in the rat or
mouse hepatocytesfollowingin vivoexposure. Likewise, UDSin ratandmousehepatocytesin vitrowasnot
induced by EB orDEB. Salmonella typhimurium genemutation (Ames)testsof1,3-butadiene usingstrains
TA1535, TA97, TA98, and TA100 and employing rat, mouse, and human liver S9 metabolic systems were
barely2-foldabovebackgroundonlyinstrainTA1535at30%o1,3-butadieneinairwithinducedanduninduced
rat S9 and mouseS9 (uninduced). 1,3-Butadiene was negative in in vitroSCE studies in human whole blood
lymphocytes cultures treated in the presence of rat, mouse, or human liver S9 metabolic activation. In
general, 1,3-butadiene is genotoxic in vivo but is a weak in vitro genotoxin.
Introduction
1,3-Butadiene is a potent carcinogen in B6C3F1 mice
(1,2) but only weakly tumorigenic in Sprague-Dawley
rats (3). These differences in carcinogenic potency have
raised the question as to which of the two species, if
either, is the better indicator of the human response.
Studies evaluating the mutagenic response to 1,3-bu-
tadieneinvivoandinvitroinrodentsandhumansshould
permit a more quantitative estimation of toxicological
differences between manandrodents. We examined the
possibility that the genotoxicity of 1,3-butadiene or
genotoxic metabolites is a major contributing factor to
its carcinogenic activity in rodents.
Two known genotoxic metabolites, 3,4-epoxybutene
(EB) and 1,2:3,4-epoxybutane (DEB) areformed invivo
(4) and in vitro (5,6) and both bind covalently to DNA
(7-9). 3,4-Epoxybutene wasreported tobegenotoxicin
Klebsiella and Salmonella (10) and induce sister chro-
matid exchange and chromosome aberrations in mice
(11,12). DEB was also genotoxic in a variety of pro-
karyotic and eukaryotic organisms in vitro (13-17).
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1,3-Butadiene has been shown to be genotoxic in the
Salmonella mutation assay (18-20) and in vivo in mice
(21-23); it is, however, negative in rats (21). Since
1,3-butadiene must be metabolized to exhibit geno-
toxicity (19), the metabolic competence of different
species may determine the putative hazard in that
species. Preliminary findingsindicated that mouse liver
homogenates are more active in producing EB than
correspondingrat orprimate (includinghuman) homog-
enates (24). Similarly, mouse lung homogenates gener-
ate more metabolites than ratlunghomogenates. Kreil-
ing et al. (25) reported that the maximal metabolic
elimination rate of 1,3-butadiene in the mouse is nearly
twice that ofthe rat. Blood concentrations of EB were
two to five times higher in 1,3-butadiene-treated
B6C3F1 mice than Sprague-Dawley rats (4). We chose
to look atthe effects ofdifferent species sources ofliver
homogenates as our activation system to determine if
1,3-butadiene metabolism was a contributing factor to
the genotoxic differences between species.
Salmonella typhimurium Assay Using
Rat, Mouse, and Human S9
StudiesbydeMeesteretal. (19)indicatedthat1,3-bu-
tadiene induced mutations in Salmonella typhimurium
TA1530inthepresenceofAroclor1254-induced ratliver
S9 and mouse liver microsomes. No mutations in the
presence ofuninduced rat liver S9 were observed. WeARCE ET AL.
Table 1. Revertants of strain TA1535 treated with 1,3-butadiene
with and without various S9 activations systems.a
TA1535 revertants/plate
1,3-butadiene Rat S9 Rat S9 Mouse S9 Human S9
(in air) Aroclor uninduced uninduced uninduced No S9
0 21 4 20 0 32 ± 4 22 ± 10 25 ± 4
30 55 5 42 5 68 ± 6 32 ± 12 31 ± 0
40 48 1 NTb 50 ± 10 41 1 37 ± 2
50 52 15 41 + 4 47 ± 1 39 3 43 1
60 40 6 NT 31 ± 3 42 6 37 4
2-AAb 1237 7 200 ± 52 255 ± 14 578± 13
NaAzb 888 ±2
aAll S9 concentrations were 0.8 mg protein/plate. Experimental
error is expressed as standard deviation between plates.
bAbbreviations: NT, not tested; 2-AA, 2-aminoanthracene, 2 ,ug/
plate; NaAz, sodium azide, 2 ,ug/plate.
investigated the capability ofAroclor 1254-induced rat,
and uninduced rat, mouse, and human S9 to activate
1,3-butadiene into genotoxic metabolites as detected by
the Salmonella mutation assay (26) using strains
TA1535, TA97, TA98, and TA100. All S9 preparations
were made according to the procedure of Ames et al.
(26). Design concentrations of 1,3-butadiene gas were
metered into specially constructed treatment chambers
holding the agar plates overlaid with the bacteria and
activation system. Actual gas concentrations were de-
termined by gas chromatographic analysis before and
after the 48-hr exposure. Because 1,3-butadiene is ex-
plosive at concentrations between 2 to 12% in air, the
lowest dose that could be tested safely was 30%. Differ-
ent treatment chambers were used for each activation
system and for the nonactivated treatment.
1,3-Butadiene induced revertants only in strain
TA1535 (Table 1). Mouse S9 showed slightly higher
activity than the uninduced rat or human S9 at 30%
1,3-butadiene in air. At concentrations exceeding 30%,
the number of revertants decreased in the presence of
rat or mouse S9. Results from the human S9-activated
treatments did not differ substantially from those ofthe
nonactivated treatments. Aroclor 1254-induced rat S9
gave similar results as mouse S9 (uninduced). Since the
response was weak, the S9 concentration was increased
from 0.8 mg/plate to 4.0 mg/plate (Table 2). Increasing
the concentration ofAroclor 1254-induced rat S9 had no
effect onthe numberofrevertants; slightly morerevert-
ants were observed using 4.0 than 0.8 mg/plate ofunin-
duced rat S9.
These Salmonella typhimurium results differ from
de Meester's (19) in two ways. First, the level of mu-
tagenicactivity wassubstantially lowerwithinducedrat
S9 than reported by de Meester (19). Second, we were
able to detect a weak response in strain TA1535 with
uninduced rat S9. Differences in 1,3-butadiene and S9
protein concentrations and strains TA1530 versus
TA1535 are probably the source ofthis interlaboratory
variation.
Table 2. Revertants of strain TA1535 treated with 1,3-butadiene
with varying concentrations of Aroclor 1254-induced and
uninduced rat S9.
% 1,3 U Aroclorg 1254-induced
butadiene Uninduced rat S9 rat S9
(in air) 0.8 mg/plate 4.0 mg/plate 0.8 mg/plate 4.0 mg/plate
0 20 0 21 3 23 2 18 ± 1
30 42 5 60 10 45 3 46 ± 1
50 41 4 57 3 48 2 50 ± 24
2-AAM 200 ± 52 NTa TNTCa NTa
aAbbreviations: 2-AA, 2-aminoanthracene, 2 ,ug/plate; NT, not
tested; TNTC, too numerous to count.
Human Whole Blood Lymphocyte
SCE Assays
Human whole blood lymphocytes were also used to
investigate the ability of rat, mouse, and human S9 to
activate 1,3-butadiene to genotoxic metabolites using
SCE as the biological marker (27). Design con-
centrations of1,3-butadiene gas were metered into spe-
cially constructed treatment chambers holding the cul-
ture flasks. Actual gas concentrations were determined
by gas chromatographic analysis.
The average generation time and mitotic index ofthe
cultured cells were unaffected by 1,3-butadiene treat-
ment in the presence of S9; although in the presence of
1,3-butadiene and mouse S9, cells were beginning to
demonstrate a dose-responsive decrease in average ge-
neration time (data not shown).
No positive SCE or dose responses were observed
with or without any of the activation systems at 25 to
100% 1,3-butadiene in nitrogen (Table 3). In contrast,
Table 3. Sister chromatid exchanges in human whole blood
lymphocytes treated with 1,3-butadiene in the absence and
presence of rat, mouse, or human S9.a
% 1,3-
butadiene Rat S9 Rat S9 Mouse S9 Human S9
(in N2) Aroclor uninduced uninduced uninduced No S9
0 4.3±1.4 4.9±1.1 8.4±2.6 4.6±1.6 3.8±0.8
25 3.8 ± 0.7 5.9 ± 1.1 7.0 ± 2.0 5.1 ± 1.0 4.1 ± 0.7
100 4.3 ± 0.5 6.2 ± 0.3 9.3 ± 2.3 5.1 ± 0.7 4.9 ± 0.8
Cpb CAb 11.1 ± 2.1 20.8 ± 8.2 7.5 ± 2.5
MMCb 19.7 ± 0.8
aMaleandfemale humanlymphocyteswereusedforeachstudywith
a different preparation of liver S9 fraction used for the second trial.
Only one trial was performed with Aroclor 1254-induced rat S9.
Whole blood cultures were initiated by inoculating 0.3 mL of whole
blood into 4.7 mL of supplemented RPMI 1640 with 1.5 to 1.9%
reconstituted phytohemagglutinin. Cultures were incubated 48 hr
prior to treatment. All activated treatments contained S9 at a final
concentration of 1 mg protein/mL. Cultures were exposed to 1,3-bu-
tadienefor4hr, washed; 5mLculturemediumcontained 10 ,iM BrdU
wasadded;2hrpriortoa24-hrharvest0.1,ug/mLcolcemidwasadded.
SCE analysis was performed as described by Cunningham et al. (21).
Atleast25cellspertreatmentgroupwerescored. Experimental error
is expressed as the standard deviation between cultures.
bAbbreviations: CP, cyclophosphamid, 25jig/mL; MMC, mitomycin
C, 0.25jig/mL; CA, chromosomalaberrationswereobservedincellsin
firstdivision;however, toxicitywastooexcessiveto scoreSCEswhich
required cells to have completed two rounds ofcell division.
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Table 4. In vivolin vitro unscheduled DNA synthesis in rat and
mouse hepatocytes in animals exposed to 10,000 ppm
1,3-butadiene.'
Net grain count cell
Treatmentb Mouse Rat
Air, 2 hr -0.9 ± 0.3 -1.7 ± 0.4
1,3-Butadiene, 2 hr +0.4 ± 0.4 -0.6 ± 0.6
DMBA +16.0 ± 2.0 +45.2 ± 10.4
Air, 18hr -6.3 ± 1.2 -4.1 ± 0.8
1,3-Butadiene, 18 hr -3.7 ± 0.6 -5.2 ± 0.8
DMBA +19.8 ± 6.3 +40.8 ± 4.4
'The air control and each 1,3-butadiene treatment consisted oftwo
animals per species with two slides scored per animal. A minimum of
100 cells were scored for each treatment group. The positive control
was treated in vitro from the animals used in the air exposure. A
minimum of75 cells were scored. The error is expressed as the SE of
the mean between the average net grain counts per slide in each
treatment.
bAbbreviations: 1,3-butadiene, 2 hr = 1,3-butadiene exposure for6
hr onday 1 and3hr onday2with2hrpostexposure time(repairtime);
1,3-butadiene, 18 hr = 1,3-butadiene exposurefor6hrfor2dayswith
a 18-hrpostexposure time; DMBA, dimethylbenzanthracene (100 ,uM)
18-hr treatment in vttro.
both cyclophosmid and mitomycin C induced SCEs for
activated and nonactivated treatments, respectively.
In Vivo/lIn Vitro Unscheduled DNA
Synthesis and In Vitro Assays
In the in vivo/in vitro unscheduled DNA synthesis
(UDS) assay (28), two 1,3-butadiene exposure/sampling
protocols were employed. Male Sprague-Dawley
(Crl:CD BR) rats and B6C3F1 (B6C3F1/CrlBR) mice
were exposed nose-only to either air or air containing
10,000 ppm 1,3-butadienefora) 6hr onday 1 followedby
3 hr on day 2; livers sampled 2 hr after the end of the
second exposure, and b) 6 hr/day for 2 days; livers
sampled 18 hr after the second exposure. [See Cun-
ningham et al. (21) for inhalation conditions.] No UDS
was evident in either species under those conditions
(Table 4).
In the UDS assay in rodent hepatocytes in vitro (29),
test concentrations of EB and DEB ranged from 5 to
1000 ppm in medium. Both metabolites were cytotoxic
above 5 ppm, as evidenced by a decrease in nuclear and
cytoplasmic grain counts. No cell survival was obtained
at concentrations above 1000 ppm. Both EB and DEB
failed to induce UDS in rat and mouse hepatocytes.
Slight increases in the net nuclear grain counts were
evident; however, they appear to be the result ofDEB-
and EB-induced cytotoxicity, as evidenced by a signifi-
cant drop in grain counts over the cytoplasm. Table 5
displays anexampleoftheeffectofEB onrathepatocyte
cultures.
In Vivo Genotoxicity in Rodent Bone
Marrow
Male Sprague-Dawley rats and B6C3F1 mice were
exposed to 1,3-butadiene by nose-only inhalation at con-
Table 5. In vitro unscheduled DNA synthesis in rat hepatocyte
cultures treated with 3,4-epoxybutene.a
3,4-Epoxybutene, Nuclear Cytoplasmic Net
ppm in medium grains/cell grains/cell grains/cell
0 22.4 ± 0.6 29.1 ± 0.8 -6.6 ± 0.7
5 27.2 ± 1.9 35.0 + 1.9 -7.7 ± 2.0
50 11.1 ± 0.5 11.1 ± 0.2 +0.1 ± 0.5
100 9.3 ± 0.5 8.6 ± 0.1 +0.7 + 0.5
1000 7.9 ± 0.5 7.1 ± 0.5 +0.8 ± 0.3
DMBAb 62.3 ± 4.8 33.4 ± 0.5 +29.0 ± 4.4
a3,4-Epoxybutene was dissolved in DMSO. Each treatment group
consisted offourcultures with25 cells scored perculture. Theerroris
expressed as the SEM between cultures.
bDMBA, dimethylbenzanthracene.
centrations of 10 to 10,000 ppm for 6 hr/day for 2 days.
SCE and micronucleus (MN) induction were sub-
seqvientlymeasuredinthebonemarrow(21). Toxicityof
1,3-butadiene was observed at 10,000 ppm as measured
by polychromatic erythrocyte (PCE) suppression [ex-
pressed as the ratio of PCE/NCE (normochromatic
erythrocytes)] in bone marrow. This was a possible
indication that 1,3-butadiene and/or its metabolites
reached the bone marrow and exerted toxicity.
Cunningham et al. (21) demonstrated MN frequency
inthemouse bone marrowincreased as afunctionofBD
concentration, beginningat 100ppm(0.44% micronucle-
ated PCEs) and reaching 3.0% at 10,000 ppm. No in-
crease above the control MN frequency (0.08%) was
detected at orbelow50ppm. Incomparison, there were
no statistically significant increases in MN frequency in
rats exposed to the same 1,3-butadiene levels as mice.
Analysis for SCE inthe ratand mouse led to a similar
conclusion. At 100ppm, significantincreasesin SCE (20
SCEs/cell) were obtained inthe mouse, reaching amax-
imal response of 30 SCEs/cell at 200 ppm compared to
controllevelsof8.5SCEs/cell. Thenoeffectlevelwas50
ppm. No significant effects were observed in the rat at
concentrations up to 10,000 ppm (21).
Discussion
1,3-Butadiene is genotoxic in the mouse but notin rat
bonemarrowcells. Thegenotoxicresponseinthe mouse
parallelsthetumorigenicitydata(2). Theresultsarealso
in agreement with the findings (22,30) that 1,3-bu-
tadiene affects mouse bone marrow stem cell develop-
mentandinducesmacrocyticmegaloblasticanemia. The
absenceofagenotoxicresponseintheratalsocorrelated
relativelywellwiththelowtumorincidenceandabsence
ofchronic toxicity in the hematopoietic system (3). Be-
cause 1,3-butadiene failed to induce UDS in rodent he-
patocytes in vivo nor did EB/DEB in vitro, it could be
concluded that the genetic damage induced by BD or
EB/DEB is not repaired by excision repair.
ThedifferencesinSCE andMNinductionbetweenthe
rat and mouse may be due to the metabolic and phar-
macokinetic properties of 1,3-butadiene in the two
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species. Schmidt and Loeser (24) demonstrated that
mouse liver and lung postmitochondrial fractions, when
treated with 30,000ppm 1,3-butadiene, generated more
EB than the respective rat homogenates. This argu-
ment, however, is weakened by the lack ofa genotoxic
response in human lymphocytes when using either Aro-
clor 1254-induced rat, uninduced rat, mouse, or human
liver homogenates, and by the weak response of1,3-bu-
tadiene in the Salmonella assay.
Our studies and those of others show that 1,3-bu-
tadiene is apotent invivogenotoxin in the mouse, but a
weak genotoxin in vitro. Physiological factors in the
mouse not present in the in vitro test systems may
contribute to the genotoxic effects in mouse bone mar-
rowcells. Thesignificance oftheseresultstohumanrisk
is presently unknown.
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